New technology for creating radiolabeled peptides for imaging and treatment
Official title: Catch and Release Radiolabeled Peptides: a new technology for radiotracer development
Funded at State University New York Stony Brook · NIH-10885928 · Data updated 2026-11-12
This study is working on a new way to make special tiny proteins that can help doctors see and treat cancer better, using smart technology to make the process easier and more effective for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project start | July 15, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $201,889 |
| NIH project number | 5R21EB032495-02 |
| Project ID | NIH-10885928 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing evaluation or treatment for cancers or other conditions that could benefit from advanced imaging techniques.
✕Less likely to help
Patients with conditions that do not require imaging or treatment involving radiolabeled peptides may not benefit from this research.
What this research studies
This research focuses on developing a novel method for creating radiolabeled peptides, which are important for imaging and treatment in various medical fields, particularly oncology. The approach utilizes advanced automation and innovative chemistry to produce high-purity radiotracers that can be easily integrated into existing peptide synthesis processes. By streamlining the production of these peptides, the research aims to enhance their application in drug discovery and clinical settings, ultimately improving diagnostic and therapeutic options for patients. The project seeks to leverage existing technologies to create a robust platform for the synthesis and evaluation of these valuable compounds.
Why it matters
Potential benefit: If successful, this research could lead to more effective imaging and treatment options for patients with various conditions, particularly cancers.
How similar studies have gone: Other research has shown promise in the use of radiolabeled peptides for imaging and treatment, indicating that this approach has the potential for significant advancements.
Where this research is happening
-
State University New York Stony Brook
Stony Brook, United States Active
Researchers
- Principal investigator: Parker, Matthew — State University New York Stony Brook
- Study coordinator: Parker, Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.